Valion Bio, Inc. — Form S-1
Filed July 17, 2026 · analyzed by the Registration Agent
S-1
— Neutral
significance 18/100
What the filing says
Valion Bio filed Form S-1 registering up to $30M in common stock, pre-funded warrants, and common warrants. Dawson James Securities is placement agent receiving warrant compensation (6% of offering, ~$990K estimated). Securities Purchase Agreement permits investors to elect pre-funded or common warrant combinations; all documents include standard warrant mechanics, anti-dilution provisions, and 5-year exercise periods.
Why this rating
Standard IPO/registered offering documentation. No deal dollar amounts, counterparty names (beyond generic 'Purchasers'), or current status disclosed. At $4M market cap, any capital raise would be material, but filing is templated boilerplate with blank terms.
See more from July 17, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.